Aerial view of Children's Mercy Hospital

Children's Mercy Hospital is one of twenty-five type 1 diabetes TrialNet International Clinical Centers at the forefront of type 1 diabetes research. Led by Wayne Moore, MD, PhD the TrialNet team at Children's Mercy is dedicated to preventing type 1 diabetes and stopping disease progression by preserving insulin production before and after diagnosis.

Our Team

Portrait photo

Wayne Moore, MD, PhD

Dr. Moore is Co-Principal Investigator for the Clinical Center at Children’s Mercy Hospital in Kansas City. His primary interests in diabetes research have been prevention of diabetes and its complications at a translational and clinical level. He is a Certified Physician Investigator through the Association of Clinical Research Professionals. Dr. Moore has been at Children’s Mercy Hospital for over 20 years and was at University of Kansas Medical Center prior to Children’s Mercy. MD, PhD and Pediatric Residency were completed at University of Minnesota.
 

Portrait photo

Mark Clements, MD, PhD

Dr. Clements is Co-Principal Investigator for the Clinical Center at Children’s Mercy Hospital in Kansas City.  His primary interests in diabetes research have been prevention of diabetes and its complications, and the use of big data  predictive analytics to improve diabetes care.  He is a Certified Physician Investigator through the Association of Clinical Research Professionals.  Dr. Clements has been at Children’s Mercy Hospital for 13 years. He attended Butler University, then trained in the Medical Scientist Training Program (MD/PhD program) at Washington University in St Louis. He completed his Pediatric Residency and Endocrine/Diabetes Fellowship at Children’s Mercy Kansas City.

Portrait photo

Lena Huerta-Saenz, MD

Dr. Huerta-Saenz is a pediatric endocrinologist at the Children’s Mercy Wichita specialty clinic, and Adjunct Assistant Professor of Pediatrics at the University of Missouri, Kansas City. She also has a joint appointment at the Kansas University -Wichita School of Medicine as a Clinical Assistant Professor. Dr. Huerta-Saenz, has experience monitoring clinical trials and has advanced training in “Good clinical practices”. She worked as a clinical research associate at Quintiles Transnational Inc. for 2.5 years, and performed monitoring of phase 2 &3 multicenter clinical trials before her training as a pediatrician. Dr. Huerta-Saenz also has prior experience performing site selection; site monitoring and site close out visits for clinical trials. She also received further statistic analysis training at Pontificia Universidad Catolica del Peru receiving a diploma in applied statistics.

Ryan McDonough

Ryan McDonough, DO, FAAP

Ryan McDonough, DO, FAAP is a Pediatric Endocrinologist and the Co-Medical Director of the Children’s Diabetes Center.  His expertise is in the use of clinical and medical informatics to improve management of clinical trials and health care delivery, and in the care of children and adolescents with Type 1 Diabetes.  His role in the Clinical Center is recruiting and assisting in prevention trials.  He completed his medical school at Des Moines University in Des Moines, IA, and Pediatrics Residency and Pediatric Endocrinology & Diabetes Fellowship at Children’s Mercy.

Fadi

Fadi Al Muhaisen, MD, FAAP

Fadi Al Muhaisen, MD, FAAP is a Pediatric Endocrinologist and the Co-Medical Director of the Endocrine Disorders in Cancer patients clinic. He has a joint appointment at the Kansas University-Wichita School of Medicine as a Clinical Assistant Professor. His expertise is in the use of clinical and research to improve management of clinical trials and health care delivery, and in the care of children and adolescents with Type 1 Diabetes. His role in the Clinical Center is recruiting and assisting in prevention trials. Dr. Al Muhaisen is a member of the American Academy of Pediatrics, board certified, and a member of Pediatric Endocrine Society

Portrait photo

Misty Whisenhunt , RN

Portrait photo

Lois Hester, RN, CCRC

Portrait photo

Darlene Brenson-Hughes

jennifer james

Jennifer James, BA

Portrait photo

Julie de la Garza, RN, BSN, CCRP

Portrait photo

Jen Bedard, BA, CCRC

Portrait photo

Liz Ramey, MS, RD, LD

Portrait photo

Aliza Elrod

Dara Watkins

Dara Watkins, MA, CCRP

Susan

Susan Mitchell, RN, BSN

casey

Casey McClain, BPS, MHA, CCRC

erica

Erica Livingston, RN

kelsye

Kelsye Howell, RN

Jill

Jill Sexton, RN

Barb

Barb Seuferling, RN

Steve Oerlich

Steve Orlich, RN, ACRP-CP

Regional Affiliates

Affiliates provide opportunities for people who do not live near a TrialNet Clinical Center. The affiliate sites listed below work with Children's Mercy to offer convenient participation in our research programs 

University of Missouri
CRC-N508 Health Science #1, Hospital Dr , Columbia, 65212 United States
Truman Medical Center
2411 Holmes St, SOM M4-329 , Kansas City, 64108 United States
KU Diabetes Institute - University of Kansas Medical Center
3901 Rainbow Blvd. MS 1064 , Kansas City, 66160 United States
University of Nebraska Medical Center
985456 Nebraska Medical Center , Omaha, 68198 United States

Research Studies

Risk Screening Risk Screening

If you have a relative with T1D, you may be eligible for risk screening that can detect the early stages of T1D years before symptoms appear. More

Monitoring Monitoring

Depending on your risk screening results, you may be eligible for monitoring. We’ll monitor you for disease progression and let you know if you become eligible for a study. More

Prevention Study Hydroxychloroquine (HCQ)

We are testing the drug hydroxychloroquine (HCQ) to see if it can delay or prevent early stage T1D (stage 1) from progressing to abnormal glucose tolerance (stage 2) and ultimately prevent clinical diagnosis (stage 3). HCQ is already used to reduce symptoms and progression of other autoimmune diseases, such as rheumatoid arthritis and lupus. This is the first study to see if it can prevent or delay T1D. Details

Prevention Study Abatacept Prevention Study

TrialNet is testing the drug abatacept to see if it can delay or prevent progression of early stage T1D (stage 1 or stage 2), and ultimately prevent clinical diagnosis (stage 3). In earlier studies for people newly diagnosed (stage 3), abatacept helped slow down disease progression. Details

Long Term Longterm Follow-up

If you are diagnosed with T1D while participating in one of our prevention studies, we’re still here for you. You can continue to receive personal monitoring while helping us learn more. More